Physician profile
Stephen R Pace
NPI 1487141420
$4,896.37
in general payments reported to CMS, 2019-2025
39 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $452 · 2023: $1,288 · 2024: $1,469 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,444.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $767.50 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $632.19 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $429.89 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $419.76 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $356.25 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.86 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $228.77 | 2023-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $213.56 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $206.91 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.78 | 2023-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $143.22 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Daiichi Sankyo INC. | $90.76 | 2024 | Injectafer |
| Novo Nordisk INC | $76.86 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $71.13 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $70.70 | 2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.02 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.81 | 2022 | |
| Merck Sharp & Dohme LLC | $53.36 | 2022-2024 | Verquvo, Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.13 | 2025 | Caplyta |
| Lundbeck LLC | $48.13 | 2023-2024 | Rexulti |
| Viatris Specialty LLC | $46.68 | 2025 | Yupelri |
| Exact Sciences Corporation | $45.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Averitas Pharma INC. | $39.42 | 2023-2024 | Qutenza |
| Inspire Medical Systems, INC. | $28.77 | 2025 | Inspire |
| Vertex Pharmaceuticals Incorporated | $27.52 | 2025 | |
| Axsome Therapeutics, INC. | $26.52 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $25.65 | 2023 | Quviviq |
| Mylan Specialty L.P. | $22.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.09 | 2024 | Givlaari |
| Irhythm Technologies, INC. | $19.24 | 2024 | Zio Monitor, Zio Xt Patch |
| Abbott Laboratories | $18.77 | 2025 | Freestyle Libre 3 |
| Cvrx, INC. | $18.73 | 2024 | Barostim Neo System |
| Teva Pharmaceuticals USA, INC. | $18.71 | 2022 | |
| Corium, LLC | $18.62 | 2023 | Adlarity |
| Medtronic, INC. | $17.57 | 2024 | Intellis Adaptivestim |
| Aimmune Therapeutics, INC. | $16.57 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $14.68 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $13.57 | 2023 | Contrave, Onzetra Xsail |
| Sanofi-Aventis U.S. LLC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.